BEaTS Research Radio's Podcast

Anastasia Fahlman and Sarah Damiani from the University of Ottawa speak with Dr. Erin Mulvihill, Scientist and Director of the Energy Substrate Metabolism Research Laboratory at the University of Ottawa Heart Institute. Tune in to learn more about her recent work published in CellPress, which explores the potential mechanisms underlying the cardioprotective benefits of metabolic surgery and GLP-1RA-based therapies. It also discusses recent evidence and emerging therapies in this dynamic area of research. Learn more: https://www.sciencedirect.com/science/article/pii/S1043276024001930                                                                     Credits for music: Soundtracks by the Underground Drive. All rights reserved. Listen more: https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmRPodcast by Sarah Damiani (Voice, Producer, Show Co-Host, Writer Editor, Audio Master) and Anastasia Fahlman (Voice, Show Co-Host, Writer Editor, Audio Mast

Matteus McCulloch from the University of Ottawa interviews Dr. Michele Ardolino, a senior scientist in cancer research at the Ottawa Hospital Research Institute and an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. In this episode, Dr. Ardolino discusses a recent paper published by his lab about PD-L1 and its inhibition of the Type I IFN pathway during oncolytic virus infection, how the research came about, and the relevance of the work to advance cancer treatment.  Learn more about Dr. Ardolino and the work of the Ardolino Lab: https://www.uottawa.ca/faculty-medicine/dr-michele-ardolino https://ardolinolab.ca/0:00 | Introduction to PD-L1 and the type I IFN pathway and its relevance to recent research by Hodgins, J.J. et al. 1:40 | BEaTS, host, and guest introduction2:18 | What inspired the Ardolino Lab's exploration of PD-L1 and the type I IFN pathway?5:01 | What setbacks were encountered over the course of this study?6:35 | What is the me

In this episode, Ali Abdalbari from the University of Ottawa's Translational and Molecular Medicine (TMM) program speaks with Dr. Morgan Fullerton, Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. This episode features a discussion surrounding Dr. Fullerton’s most recent paper, published in the Atherosclerosis Journal (https://doi.org/10.1016/j.atherosclerosis.2024.117608). Dr. Fullerton provides an in-depth overview of his team’s discoveries and offers his expertise in the field of metabolic research, highlighting the importance of model systems of disease and the implications of his research in this field.Learn more: https://doi.org/10.1016/j.atherosclerosis.2024.117608 Fullerton Lab: https://www.fullertonlab.com/0:10 | BEaTS and host introduction0:39 | Introduction to Dr. Fullerton1:39 | Podcast topic introduction1:56 | Guest welcome2:08 | Introduction to atherosclerosis3:44 | Focus of the Fullerton lab: metabolism and AMPK6:32 | Interlude: a study

In this episode, Celina Tanbari from the University of Ottawa interviews Dr. Adam Rudner about the fascinating world of bacteriophages—viruses that target and kill bacteria. Dr. Rudner is the coordinator of the University of Ottawa’s Phage Hunters program, a member of the SEA-PHAGES and SEA-GENES programs, and an Associate Professor in the Department of Biochemistry, Microbiology, and Immunology. Dr. Rudner shares with us his expert opinion on a study that isolated bacteriophages from human skin to kill infection-causing bacteria. The discussion delves into the therapeutic potential of phages, their involvement in biofilms and lysogeny, and the challenges associated with utilizing phages in medicine. This episode was produced and written by Emma Etchells Foisy, hosted by Celina Tanbari, and audio edited by Sam Rogers. Copyrights are reserved to BEaTS Research Radio and the University of Ottawa.If you are interested in learning more about the paper we discussed today, you can find it through the following link

Maheen Khanotia from the Translational Molecular Medicine program interviews Dr. Barabara Vanderhyden, a distinguished researcher at the Ottawa Hospital and a professor at the University of Ottawa. She is a leading researcher in ovarian cancer, focusing on the BRCA1 and BRCA2 mutations. In this podcast, Maheen discusses with Dr. Vanderhyden her key findings in her 2023 paper "BRCA1 and BRCA2 deficient tumor models generate distinct ovarian tumor microenvironments and differential responses to therapy," where they delve into the world of cancer, Dr. Vanderhyden's lab findings, potential treatments, and research advice.Learn more:  https://www.ohri.ca/profile/vanderhydenlab/profile0:05 | BEaTS and host introduction.1:17 | Introduction to Dr. Barbara Vanderhyden.1:39 | How did you come to study ovarian cancer?2:48 | What led you to believe the BRCA1 and BRCA2 mutations are different?3:50 | What is the tumor microenvironment? 4:57 |  What do the research findings mean to the general public?6:05 | W

Lia Morton from the University of Ottawa interviews Dr. Marisa Azad. Dr. Azad is a physician-scientist at the Ottawa Hospital Research Institute and an Assistant Professor of medicine in the division of infectious diseases at the University of Ottawa. In this episode, Dr. Azad shares her insight and expertise on implant-associated infections (IAIs), notably the challenges of detecting and diagnosing IAIs and emerging diagnostic methods.Learn more: https://www.ohri.ca/newsroom/story/view/1543?l=en   0:00 | BEaTS and host introduction.0:38 | Introduction to Implant-Associated Infections (IAIs)1:40 | Introduction to Dr.Azad.2:11 | Why is IAI diagnosis so difficult, and what makes it particularly challenging?3:39 | Implant types that are notably hard to detect.4:29 | How do biofilms contribute to the formation of IAIs, and what makes them dangerous?7:41 | Limitations associated with microbiological analyses.11:09 |Future work and new approaches considered to identify IAIs.12:59 |The diagnostic methods currently b

Join Kahliana Nguyen and Khaled Najjar, Translational and Molecular Medicine students, as they speak with Dr. Baptiste Lacoste, a neuroscience researcher at the Ottawa Hospital Research Institute whose recent work focuses on the critical role of the brain’s vascular system in development.  The episode explores a new perspective on autism spectrum disorders (ASD) and how problems with the brain’s blood vessels in early development may contribute to challenges seen in autism. Dr. Lacoste goes into depth on how these blood vessels play a role in brain growth, energy use, and behavior. By studying these interactions alongside neural and genetic factors, his research opens new avenues in how we understand autism and find better ways to address ASD. Whether you’re a researcher, student, or simply curious, this episode offers an exciting new lens to the field. Learn more: Dr Baptiste Lacoste Dr Baptiste Lacoste | Faculté de médecine https://bsky.app/profile/blacoste.bsky.socialhttps://www.ohri.ca/profile/lacostelab0

Maryam Yassin from the University of Ottawa interviews Dr. Anna Jezierski and Dr. Alex MacKenzie. Dr. Jezierski is a research officer at the Department of Translational Biosciences in the Human Health Therapeutics Research Center at the National Research Council of Canada. She is also an adjunct professor for the Department of Biochemistry, Microbiology, and Immunology at the University of Ottawa. In this episode, Dr. Jezierski shares her research on modeling the human blood-brain barrier using induced pluripotent stem cells and the various applications of this model in studying therapeutics for diseases of the central nervous system. We're also joined by Dr. Alex Mackenzie, an attending pediatrician and senior scientist at the Children's Hospital of Eastern Ontario (CHEO). He has served as the CEO and Scientific Director of CHEO Research Institute and is a cross-appointed member of the Faculty of Medicine at the University of Ottawa. Dr. Mackenzie comments on how this model is revolutionizing drug

A series of interviews with presenters and participants at the Music and Health Research Institute's annual conference at The Royal Ottawa Mental Health Centre. This episode serves as an introduction to the ongoing work of institute members in the field of Music and Health research and practice.  Lucas Marchand (Interviewer, Post-production, Content generation, Producer)Learn more: https://www.uottawa.ca/research-innovation/music-health 0:02 | Host introduction.0:29 | Interview with Dr. Jane Gosine of Memorial University 2:15 | Interveiw with Ludovic Dubé4:34 | Interview with Dr. Chi Lo of Singwell9:45 | Interview with Dr. Erin Parks of Lotus Centre14:15 | Interview with Cory Butler of Zamar MusicOriginal music written and recorded by Lucas Marchand 

Deyanira Hernandez de la Universidad de Ottawa, habla con la Dra. Daniela Gordillo Bastidas, Directora Nacional del programa de Nutrición y Bienestar Integral del Tecnológico de Monterrey. En este episodio se abordan temas relacionados con medicamentos en el tratamiento de diabetes y diminución de peso, así como posibles efectos secundarios y criterios de evaluación para su prescripción.Acerca del Tecnológico de Monterrey: https://tec.mx/en1:39 -  El medicamento Ozempic originalmente se desarrolló como un medicamento para la diabetes tipo 2, sin embargo, ha ganado mucha popularidad en los últimos años, especialmente por su uso en la pérdida de peso. ¿Podría explicarle a nuestra audiencia cómo es que este tipo de medicamentos actúan en nuestro cuerpo?5:45 - ¿Qué consideraciones debería de tener en cuenta el personal de salud antes de prescribir este medicamento y cuáles podrían ser efectos secundarios de su uso?10:38 - En su experiencia, ¿cómo considera que se puede integrar a medicamentos como lo es ozempic e